These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31335859)

  • 1. Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis.
    Chen H; Chen C; Fang J; Wang R; Nie W; Yuan Q
    Med Sci Monit; 2019 Jul; 25():5473-5481. PubMed ID: 31335859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials.
    Villablanca PA; Holmes D; Mohananey D; Briceno DF; Núñez Gil IJ; Kargoli F; Gupta T; Kizer JR; Bortnick AE; Wiley J; Menegus MA; Pyo R; García M; Ramakrishna H; Mookadam F
    Coron Artery Dis; 2017 Aug; 28(5):395-405. PubMed ID: 28328784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis.
    Liu L; Lei H; Hu J; Tang Y; Xu D
    Drugs; 2021 Nov; 81(17):2003-2016. PubMed ID: 34731462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
    Yuan J
    BMC Pharmacol Toxicol; 2018 May; 19(1):19. PubMed ID: 29720261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
    Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
    Obonska K; Navarese EP; Lansky A; Tarantini G; Rossini R; Kozinski M; Musumeci G; Di Pasquale G; Górny B; Szczesniak A; Kowalewski M; Gurbel PA; Kubica J
    Atherosclerosis; 2013 Aug; 229(2):482-8. PubMed ID: 23672879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials.
    Komócsi A; Vorobcsuk A; Kehl D; Aradi D
    Arch Intern Med; 2012 Nov; 172(20):1537-45. PubMed ID: 23007264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of new oral anticoagulants combined with antiplatelet drugs in the treatment of coronary heart disease: Systematic evaluation and meta-analysis.
    Saiyitijiang A; Aizezi M; Zhao Y; Gao Y
    Ann Noninvasive Electrocardiol; 2022 Sep; 27(5):e12977. PubMed ID: 35715952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
    Weitz JI
    Thromb Haemost; 2014 Nov; 112(5):924-31. PubMed ID: 25030773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Anticoagulant and Antiplatelet Therapy for Peripheral Arterial Disease: A Meta-analysis of Randomized Controlled Trials.
    Tang T; Zhang M; Li W; Hu N; Du X; Ran F; Li X
    Clin Appl Thromb Hemost; 2021; 27():1076029621996810. PubMed ID: 33783251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials.
    Shao QY; Wang ZJ; Ma XT; Lin XZ; Pan L; Zhou YJ
    BMC Cardiovasc Disord; 2021 Dec; 21(1):574. PubMed ID: 34852763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis.
    Zeng X; Lincoff AM; Schulz-Schüpke S; Steg PG; Elbez Y; Mehran R; Stone GW; McAndrew T; Lin J; Zhang X; Shi W; Lei H; Jing Z; Huang W
    J Cardiol; 2018 May; 71(5):494-504. PubMed ID: 29191630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
    Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
    J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.